We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

1 surging penny stock I’d buy today at 32p

This AIM-listed penny stock has climbed 51% in 2023 so far after delivering an increase in profits and a reduction in net debt.

| More on:
British Pennies on a Pound Note

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Penny stocks are volatile-but-potentially-lucrative investments. And I’ve recently been looking for smaller companies to invest in to complement the larger firms that form the majority of my portfolio.

One business that caught my eye is Iofina (LSE:IOF), which specialises in the exploration and isolation of iodine as well as the production of speciality chemicals. At present, the company’s shares trade for 32p each and it has a market capitalisation just shy of £61m.

XXX

Here’s my take on the outlook for this penny stock.

A mineral in demand

Iodine is essential for human health. It plays a vital role in proper thyroid functioning and promoting hormone production for healthy metabolism. It’s estimated that up to a third of people worldwide are at risk of an iodine deficiency.

The price of iodine has risen steadily since early 2020, driven by demand for human health applications and X-ray contrast imaging agents. Analysts expect the market will continue to grow over the coming years.

This is good news for Iofina. The company has developed a method of extracting iodine from leftover brine in onshore oil and gas production. Its process is more environmentally friendly and cheaper than leaching nitrate ores mined from the Atacama Desert, which is the source of around 66% of the world’s iodine supply.

Strong financials

The company’s results for FY22 were encouraging. Revenue increased 8% to $42.2m and its average price per kilogram for sales of crystallised iodine rose 98% to an average of $71.20. In fact, the group saw improvement across a range of key metrics including EBITDA, profits, and cash flow.

In addition, the business also trimmed its net debt from $3m to $0.9m. This is a positive sign, considering Iofina’s balance sheet hasn’t always been this healthy. After rapid expansion in 2013, the share price had collapsed 98% by early 2016, weighed down by large debts and loss-making operations.

Regarding future expansion, the company’s focus is on expanding iodine production and its speciality chemicals business. It aims to develop new chemical compounds, reduce its reliance on its current oil and gas partners, and explore new geographic areas. It currently operates five extraction facilities in the Anadarko Basin in western Oklahoma.

Risks

Of course, Iofina is very exposed to iodine prices. Any turbulence in the market poses a clear risk if the company’s margins are squeezed as a result.

Moreover, although the firm has good relationships with energy companies operating in Oklahoma’s oil fields, there’s a limited number of fields that can be developed in the area. That said, the company isn’t near full capacity currently. Plus, it plans to diversify its revenue sources in the future.

Nonetheless, as things stand, this could potentially curtail long-term growth in the share price.

Why I’d buy this stock

Overall, it looks attractively valued to me and recent financial results have been very positive. If global demand for iodine continues to grow as the company expects, there’s considerable potential for the business to expand.

While I wouldn’t take too large a stake in any penny stock, given their volatile nature, this company could potentially help to boost my portfolio’s returns. If I had spare cash, I’d buy today.

Charlie Carman has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »